Amgen stock trades near 52-week high as Q2 2026 growth and guidance support valuation
Published on 09/03/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock (US0311621009) is trading close to its 52-week high in early September 2026, with recent quotes around USD 441.56 and a 52-week high of USD 447.03 as of September 3, 2026, putting the shares about USD 5.47 below that peak according to data compiled by Investing.com.
Q2 2026 numbers drive confidence
Amgen reported strong Q2 2026 results, with revenue of about USD 10.05 billion in the quarter, up roughly 9 percent year on year, according to an overview cited by a Simplify company profile that summarizes recent figures.
Adjusted earnings reached about USD 6.29 per share in Q2 2026, beating a consensus estimate of USD 5.62 per share as referenced in the same summary, implying a positive surprise of USD 0.67 per share and underlining the company’s operating leverage.
Guidance raised for 2026
Alongside the Q2 2026 results, Amgen lifted its full-year 2026 revenue outlook, with one summary noting guidance up to roughly USD 39.4 billion, compared with a previously lower range, according to the same Simplify-based overview of management’s projections.
The combination of Q2 revenue growth of around 9 to 10 percent and higher full-year guidance helps explain why Amgen stock has surged about 55.4 percent over the past 12 months to early September 2026, as highlighted by the price performance snapshot from Investing.com.
More background on Amgen stock
Investors can follow further reports, filings and news on Amgen to understand how earnings, guidance and the product pipeline shape the share price.
Regulatory headwind for Tavneos
On the regulatory side, Amgen is facing pressure around rare-disease therapy Tavneos after the United Kingdom suspended its use for new patients and outlined an intention to fully withdraw the drug in March 2027, as reported by Yahoo Finance on September 2, 2026.
New patients in the United Kingdom can no longer start treatment with Tavneos from September 1, 2026, while existing patients have about six months to transition before an expected withdrawal of authorization on March 1, 2027, which could modestly weigh on segment revenue compared with prior expectations.
Repatha and portfolio balance
Alongside such headwinds, Amgen’s growth drivers include cardiovascular drug Repatha and other key biologics, which have helped underpin the raised 2026 revenue guidance referenced in recent summaries of the Q2 results.
For investors, the balance between expanding blockbuster franchises like Repatha and managing setbacks such as the Tavneos decision will be central to whether Amgen can sustain its current high valuation implied by a market capitalization above USD 230 billion at recent prices.
Amgen product spotlight: Repatha
Repatha, Amgen’s PCSK9 inhibitor for lowering LDL cholesterol, remains one of the company’s flagship products and a key contributor to revenue growth, with prescriptions and volumes having supported the high-single-digit to low-double-digit revenue increase reported for Q2 2026 in company and analyst summaries.
Amgen stock price snapshot
As of September 3, 2026, Amgen stock recently traded around USD 441 to USD 443 on Nasdaq, with an intraday quote of USD 439.51 reported in one snapshot and USD 442.84 in another, while the 52-week range stood near USD 269.77 to USD 447.03 and the market capitalization was about USD 239.41 billion according to compiled market data from ad-hoc-news and Investing.com.
Amgen stock key data
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Trading venue: NASDAQ
- Price (as of September 3, 2026): 439.51 USD
- Market capitalization: 239.41 billion USD (as of September 3, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: S and P 500
